BCL2 and acute myeloid leukemia: In particular, the remarkable results of Venetoclax (VEN), a specific BCL-2 inhibitor in combination with hypomethylating agents (HMAs) or low-dose cytarabine (17, 18), have led to the drug approval for the treatment of newly diagnosed unfit-for-chemotherapy AML patients (19).